Vanguard Group’s Anika Therapeutics ANIK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $7.49M | Sell |
779,165
-1,498
| -0.2% | -$14.3K | ﹤0.01% | 3101 |
|
|
2025
Q3 | $7.34M | Buy |
780,663
+1,190
| +0.2% | +$11.4K | ﹤0.01% | 3137 |
|
|
2025
Q2 | $8.25M | Buy |
779,473
+2,068
| +0.3% | +$26.1K | ﹤0.01% | 3009 |
|
|
2025
Q1 | $11.7M | Buy |
777,405
+12,135
| +2% | +$202K | ﹤0.01% | 2762 |
|
|
2024
Q4 | $12.6M | Sell |
765,270
-33,373
| -4% | -$658K | ﹤0.01% | 2820 |
|
|
2024
Q3 | $19.7M | Buy |
798,643
+8,507
| +1% | +$221K | ﹤0.01% | 2594 |
|
|
2024
Q2 | $20M | Buy |
790,136
+16,434
| +2% | +$426K | ﹤0.01% | 2568 |
|
|
2024
Q1 | $19.7M | Buy |
773,702
+9,657
| +1% | +$234K | ﹤0.01% | 2608 |
|
|
2023
Q4 | $17.3M | Sell |
764,045
-3,752
| -0.5% | -$77.6K | ﹤0.01% | 2659 |
|
|
2023
Q3 | $14.3M | Sell |
767,797
-192,909
| -20% | -$4M | ﹤0.01% | 2690 |
|
|
2023
Q2 | $25M | Sell |
960,706
-21,497
| -2% | -$575K | ﹤0.01% | 2500 |
|
|
2023
Q1 | $28.2M | Sell |
982,203
-1,565
| -0.2% | -$46.6K | ﹤0.01% | 2442 |
|
|
2022
Q4 | $29.1M | Sell |
983,768
-3,600
| -0.4% | -$102K | ﹤0.01% | 2456 |
|
|
2022
Q3 | $23.5M | Buy |
987,368
+12,125
| +1% | +$279K | ﹤0.01% | 2558 |
|
|
2022
Q2 | $21.8M | Sell |
975,243
-10,252
| -1% | -$229K | ﹤0.01% | 2600 |
|
|
2022
Q1 | $24.7M | Buy |
985,495
+19,582
| +2% | +$597K | ﹤0.01% | 2655 |
|
|
2021
Q4 | $34.6M | Buy |
965,913
+13,535
| +1% | +$542K | ﹤0.01% | 2548 |
|
|
2021
Q3 | $40.5M | Sell |
952,378
-5,323
| -0.6% | -$219K | ﹤0.01% | 2477 |
|
|
2021
Q2 | $41.5M | Buy |
957,701
+37,203
| +4% | +$1.58M | ﹤0.01% | 2469 |
|
|
2021
Q1 | $37.5M | Sell |
920,498
-13,784
| -1% | -$523K | ﹤0.01% | 2461 |
|
|
2020
Q4 | $42.3M | Buy |
934,282
+23,246
| +3% | +$882K | ﹤0.01% | 2289 |
|
|
2020
Q3 | $32.2M | Sell |
911,036
-2,207
| -0.2% | -$79.7K | ﹤0.01% | 2240 |
|
|
2020
Q2 | $34.5M | Sell |
913,243
-10,122
| -1% | -$333K | ﹤0.01% | 2184 |
|
|
2020
Q1 | $26.7M | Buy |
923,365
+7,769
| +0.8% | +$314K | ﹤0.01% | 2161 |
|
|
2019
Q4 | $47.5M | Sell |
915,596
-4,363
| -0.5% | -$253K | ﹤0.01% | 2132 |
|
|
2019
Q3 | $50.5M | Buy |
919,959
+3,701
| +0.4% | +$190K | ﹤0.01% | 2059 |
|
|
2019
Q2 | $37.2M | Buy |
916,258
+3,182
| +0.3% | +$116K | ﹤0.01% | 2252 |
|
|
2019
Q1 | $27.6M | Buy |
913,076
+33,425
| +4% | +$1.14M | ﹤0.01% | 2356 |
|
|
2018
Q4 | $29.6M | Buy |
879,651
+18,082
| +2% | +$653K | ﹤0.01% | 2269 |
|
|
2018
Q3 | $36.3M | Buy |
861,569
+8,799
| +1% | +$348K | ﹤0.01% | 2302 |
|
|
2018
Q2 | $27.3M | Buy |
852,770
+16,598
| +2% | +$684K | ﹤0.01% | 2428 |
|
|
2018
Q1 | $41.6M | Buy |
836,172
+1,202
| +0.1% | +$67.9K | ﹤0.01% | 2166 |
|
|
2017
Q4 | $45M | Buy |
834,970
+4,622
| +0.6% | +$256K | ﹤0.01% | 2112 |
|
|
2017
Q3 | $48.2M | Buy |
830,348
+23,309
| +3% | +$1.22M | ﹤0.01% | 2061 |
|
|
2017
Q2 | $39.8M | Buy |
807,039
+15,797
| +2% | +$727K | ﹤0.01% | 2124 |
|
|
2017
Q1 | $34.4M | Sell |
791,242
-53,802
| -6% | -$2.57M | ﹤0.01% | 2177 |
|
|
2016
Q4 | $41.4M | Buy |
845,044
+12,889
| +2% | +$596K | ﹤0.01% | 2074 |
|
|
2016
Q3 | $39.8M | Buy |
832,155
+14,931
| +2% | +$738K | ﹤0.01% | 2036 |
|
|
2016
Q2 | $43.8M | Buy |
817,224
+75,648
| +10% | +$3.56M | ﹤0.01% | 1959 |
|
|
2016
Q1 | $33.2M | Buy |
741,576
+102,614
| +16% | +$4.16M | ﹤0.01% | 2065 |
|
|
2015
Q4 | $24.4M | Buy |
638,962
+6,941
| +1% | +$266K | ﹤0.01% | 2217 |
|
|
2015
Q3 | $20.1M | Buy |
632,021
+32,197
| +5% | +$1.12M | ﹤0.01% | 2288 |
|
|
2015
Q2 | $19.8M | Sell |
599,824
-62,416
| -9% | -$2.23M | ﹤0.01% | 2359 |
|
|
2015
Q1 | $27.3M | Buy |
662,240
+9,391
| +1% | +$380K | ﹤0.01% | 2198 |
|
|
2014
Q4 | $26.6M | Buy |
652,849
+41,791
| +7% | +$1.63M | ﹤0.01% | 2135 |
|
|
2014
Q3 | $22.4M | Buy |
611,058
+63,557
| +12% | +$2.75M | ﹤0.01% | 2160 |
|
|
2014
Q2 | $25.4M | Buy |
547,501
+75,752
| +16% | +$3.37M | ﹤0.01% | 2127 |
|
|
2014
Q1 | $19.4M | Buy |
471,749
+96
| +0% | +$3.57K | ﹤0.01% | 2196 |
|
|
2013
Q4 | $18M | Buy |
471,653
+61,676
| +15% | +$1.9M | ﹤0.01% | 2207 |
|
|
2013
Q3 | $9.82M | Sell |
409,977
-3,947
| -1% | -$88.6K | ﹤0.01% | 2407 |
|
|
2013
Q2 | $7.04M | Buy |
+413,924
| New | +$5.97M | ﹤0.01% | 2492 |
|
Other funds holding ANIK
CP
BFM
CM
Vanguard Group's ANIK Position: Q4 2025 in Review
Vanguard Group reduced its Anika Therapeutics (ANIK) stake by 0.19% in Q4 2025, selling an estimated $14.3K and leaving 779,165 shares worth $7.49M. The position accounts for ﹤0.01% of the portfolio, ranked #3101.
Vanguard Group first reported a position in ANIK in Q2 2013 and has held it in 51 quarters since. The position peaked at $50.5M in Q3 2019. 126 funds tracked by Wall St. Rank hold ANIK as of Q4 2025.
- Vanguard Group held 779,165 shares of Anika Therapeutics worth $7.49M as of Q4 2025.
- Vanguard Group sold 1,498 Anika Therapeutics shares in Q4 2025, an estimated $14.3K.
- Anika Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3101 holding.
- Vanguard Group first reported a position in Anika Therapeutics in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Anika Therapeutics position peaked at $50.5M in Q3 2019.
- 126 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.